


### Month 4 [July] | 2021-22 | Operational Performance: Cancer

Responsible Director: Chief Operating Officer | Validated for July-21 as 1st September 2021

July-V2

NHS







<u>Ś</u>n

**FIN** 

Enc E 2 | 21Data\_F


#### National Benchmarking (June 2021)

**2WW:** The Trust was one of 8 of 13 West Midlands Trust which saw a decrease in performance between May-21 and Jun-21 This Trust was ranked 13 out of 13; where we were 8 previous month. The peer group performance ranged from 65.49% to 93.31% with a peer group average of 80.49%; declining from 82.68% the previous month. The England average for Jun-21 was 84.90% a -2.6% decrease from 87.50% in May-21.

**2WW BS:** The Trust was one of 6 of 13 West Midlands Trust which saw a decrease in performance between May-21 and Jun-21 This Trust was ranked 12 out of 13; where we were 11 previous month. The peer group performance ranged from 2.06% to 100.00% with a peer group average of 50.85%; improving from 48.74% the previous month. The England average for Jun-21 was 68.82% a 0.9% increase from 67.94% in May-21.

31 days: The Trust was one of 9 of 13 West Midlands Trust which saw a decrease in performance between May-21 and Jun-21 This Trust was ranked 4 out of 13; where we were 4 previous month. The peer group performance ranged from 84.38% to 98.50% with a peer group average of 92.21%; declining from 92.54% the previous month. The England average for Jun-21 was 94.62% a -0.5% decrease from 95.14% in May-21.

62 Days: The Trust was one of 13 of 13 West Midlands Trust which saw a Trusts in performance between May-21 and Jun-21 This Trust was ranked 8 out of 13; where we were 7 previous month. The peer group performance ranged from 44.33% to 82.46% with a peer group average of 64.53%; improving from 63.66% the previous month. The England average for Jun-21 was 73.27% a 0.3% increase from 72.97% in May-21.





### **Operational Performance: Planned Care | Waiting Lists**

2.4 - Maintain access to all emergency surgery (inc trauma) and triage elective waiting list to prioritise access for those at greatest risk of harm from delay

Servic	c Referral e (ERS) errals	RS) Service (RAS) Guidance (A&G)		Guidance (A&G)	Total RTT Waiting List	Percentage of patients on a consultant led pathway waiting less than 18 weeks for their first definitive treatment	Number of patients waiting 40 to 52 weeks or more for their first definitive treatment	Number of patients waiting 52+ weeks	Of whom, waiting 70+ weeks	Of whom, waiting 100+ weeks	
Total	7,477	Total	5,037								
Non- 2WW	4,702	Non- 2WW	4,044	2,621	53,381	53.50%	4,682	5,774	3,093	185	


#### What does the data tells us?

• ERS Referrals: a total of 7,477 electronic referrals were made to the Trust in Jul-21, the third month since Feb-21 above 7,000. 4,702 were non-2WW referrals so of the 7,759 electronic referrals 37.1% of these were 2WW cancer which is the second lowest 2WW % against any of the previous 12 months.

- **RAS Referrals:** a total of 5,037 electronic referrals were made to the Trust in Jul-21, the second consecutive month above 5,000. 4,044 were non-2WW and 76.5% were outcomed within 14 working days. Of the 626 2WW RAS referrals, 82.1% were outcomed within 2 working days. 15.7% of RAS referrals were returned to the referrer.
- **A&G Requests:** this continues to be well used and responded to in a timely manner with 2,621 A&G requests received in Jul-21 with 92.9% responded to within 2 working days and 97.4% within 5 working days.
- 71.0% of the 2,387 responses in Apr-21 to A&G requests didn't result in a referral being made for that specialty within 3 months of the response (1,634 didn't result in a referral). Further analysis is being completed into the impact of A&G activity on patient outcomes and will be reported in Sep-21.
- P Codes there has been an increase in inpatient P2 activity but the waiting list for this cohort continues to grow as more patients are clinically prioritised as urgent. The P3 cohort waiting list is decreasing, however, those waiting 70+ weeks is increasing. The waiting list for P4 patients is growing for those patients waiting less than 40 weeks.
- Referral To Treatment Time The Trust has seen a further 1.54% increase in the overall wait list size in Jul-21 compared to Jun-21; from 52,573 to 53,381.
- The number of patients over 18 weeks who have not been seen or treated within 18 weeks has increase to 24,822. This is 726 more patients than the validated Jun-21 snapshot. RTT performance for Jul-21 is validated at 53.50% compared to 54.17% in Jun-21. This remains sustained, significant cause for concern in June-21 and the 92% waiting times standard cannot be achieved.
- The number of patients waiting over 52 weeks for their first definitive treatment is currently higher than Jun-21 at 5,774 patients. Of that cohort, 3,093 patients have been waiting over 70 weeks and 185 over 100 weeks. Of the 100+ week cohort, 119 patients are under the orthodontic specialty with the next highest at 22 (urology). Looking back to those patients waiting between 71 and 100 weeks, urology is the highest at 684.

Current Assurance level: 3 (Jul-21)	When expected to move to next level of assurance: This is dependent on the programme of restoration of elective activity and reduction of long waiters
Previous Assurance Level: 3 (Jun-21)	SRO: Paul Brennan

Worcestershire



Page 86 of 182

19

July-L V2

FINAL

Enc E 2 21Data

 $\sim$ 




### **Operational Performance: RTT Benchmarking**

2.4 - Maintain access to all emergency surgery (inc trauma) and triage elective waiting list to prioritise access for those at greatest risk of harm from delay

**National Benchmarking (June 2021)** | The Trust was one of 10 of 12 West Midlands Trust which saw a increase in performance between May-21 and Jun-21 This Trust was ranked 11 out of 13; where we were 11 previous month. The peer group performance ranged from 46.58% to 82.02% with a peer group average of 56.01%; improving from 55.79% the previous month. The England average for Jun-21 was 68.80% a 1.4% increase from 67.40% in May-21.

Nationally, there were 304,803 patients waiting 52+ weeks, 5,625 (1.84%) of that cohort were our patients.

Nationally, there were 166,030 patients waiting 70+ weeks, 2,755 (1.65%) of that cohort were our patients.



NHS

20





### **Operational Performance: Planned Care | Outpatients and Elective Admissions**



2

Jata

2.4 - Maintain access to all emergency surgery (inc trauma) and triage elective waiting list to prioritise access for those at greatest risk of harm from delay

	Dutpatient Indances Face to Face Non Face to Face		% OP Attendances Non Face to Face	Firs	Consultant Led First OP Attendances		OP Follow Up OP		ive IP Case	Elective IP Ordinary		( L			
40,775	+246	29,084	+4,160	11,691	-3,914	29%	9,907	+111	12,377	-334	6,897	+192	539	-147	


#### Outpatients - what does the data tell us?

- The graphs on slide 23 compare our Jul-21 consultant led outpatient appointments to Jul-19 and our H1 activity target. Although we are not undertaking the same volume of appointments in Jul-21 compared to Jul-19, we achieved or are marginally under our total and face-to-face targets. Non-face-to-face appointments were our area of weakest performance as more patients are needing to be seen in person to determine their treatments.
- The Trust undertook 40,775 outpatient appointments in Jul-21 (consultant and non-consultant led). For context, this is 12,188 fewer appointments than Jul-19 but +233 appointments to the H1 activity target (unvalidated).
- In Jul-19, 51,639 face-to-face appointments took place compared to 29,072 in Jul-21; with the H1 target being exceeded by +4,148. As would be expected with non-face-to-face was not the norm in Jul-19, Jul-21 is considerably higher with 11,690 appointments taking place compared to 1,311. However, we are -3,915 appointments below the H1 target. Of all appointments in the month, 29% (both new and follow-up) were non-face-to-face; the ERF target is 25% or greater.
- As at 9<sup>th</sup> August, there were 27,166 RTT patients waiting for their first appointment and 6,642 of them have been dated. Of the full cohort, 1,837 patients have been waiting over 52 weeks. The top five specialties with the most 52+ week waiters in this cohort have not changed from Jun-21 and are General Surgery, Orthodontics, Urology, Oral Surgery and T&O.
- When compared to Sep-20, attendances (+8%) and clinics held (+7%) in Jul-21 are showing an increase.
- As a result of the ERF change to 95% of 19/20 activity, we continue to look to increase our patient-initiated follow-up and virtual appointments to make up the difference to the target.

#### Planned Admissions - what does the data tell us?

- On the day cancellations shows no significant change since Jun-20.
- Theatre utilisation has remained above the mean, at 77.9% and factoring in allowed downtime, this increases to 83.4%. Lost utilisation due to late start / early finish was lower in Jul-21 at 20.8% than in Jun-21 (22.7%).
- In Jul-21, we achieved the combined day case and elective inpatient H1 target; this was due to exceeding the day case plan by +214 which offset the being below the elective inpatient plan by -146. Both day case and elective inpatient saw decreases in their activity levels from Jun-21 to Jul-21.
- 67.6% of eligible patients were rebooked within 28 days for their cancelled operation in Jul-21.
- Across the Independent Sector and Wyre Valley Trust 180 day cases / electives were undertaken; this was -41 fewer compared to Jun-21.

Current Assurance Level: 4 (Jul-21)	When expected to move to next level of assurance: : This is dependent on the success of the programme of restoration for increasing outpatient appointments and planned admissions for surgery being maintained and the expectation from NSHEI for H2.
Previous Assurance Level: 4 (Jun-21)	SRO: Paul Brennan



22

July-L\_V2

IPR-,

Enc E 2 21Data

 $\sim$ 



### Month 4 [July] | 2021-22 | Operational Performance: Outpatients

Worcestershire Acute Hospitals


NHS


IPR- July-FINAL\_V2

Enc E 2 I 21Data\_F


Responsible Director: Chief Operating Officer | Unvalidated for July-21 as 9th August 2021

#### Comparing Outpatients Activity between 2019, 2021 and the H1 activity targets





Page 90 of 182





### Operational Performance: DM01 Diagnostics | Waiting List and Activity 2.4 - Ensure timely access to diagnostics and treatment for all urgent cancer care

	NHS
Worc	estershire
Acute	Hospitals
	NHS Trust

July-V2

Ż

Enc E 2 IPF 21Data\_FIN


The total waiting list, the number of	patients waiting more than 6 week	s for a diagnostic test, and % of pat	ients waiting less	than 6 weeks		
Trust Total	Radiology	Physiology			Endoscopy	
12,968 6,183 54.33% 7,804	3,222 58.71%	3,478 1,905	45.23%	1,884	886	52.97%
<ul> <li>What does the data tell us?</li> <li>DM01 Waiting List</li> <li>The DM01 performance is validated at 54.33% of patients waiting less than 6 weeks for their diagnostic test which remains consistent with the sustained underperformance since the cessation of elective diagnostic tests due to COVID-19 created a backlog of patients.</li> <li>The diagnostic waiting list has increased with the total waiting list currently at 13,166 patients, an increase of 1,691 patients from the previous month.</li> <li>The total number of patients waiting 6+ weeks has increased by 864 patients (5,149 in Jun-21) and there are now 2,218 patients waiting over 13 weeks (2,235 in Jun-21).</li> </ul>	<ul> <li>staff volunteering)</li> <li>5 GP practices have returned complete)</li> <li>Commenced discussions with license (4 reliant on discussion</li> <li>Awaiting contract approval fo process to be completed)</li> <li>Commenced BMI for CT, MRI achieving the small volume of</li> </ul>	tywide, staff permitting. (4- depends review of DEXA patients (5- updates SWBH on support with Nuc Med AF ns identifying mutual agreement) r CT mobile with Medneo (4 finance and US (5 this has commenced and	s on Obta Sept Will be Cont SAC Upda remo but c Cont sis Cont reliar Com recru	e we going to do no in contract with M ember (4 reliant or inue WLI session i ) ate CRIS with GP D ove some from wai only small number inue Nuc Med disc nt on agreement) mence recruitmen uitment campaign, mence recruitmen duled)	Iedneo to obtain s in procurement pro in CT, MRI and US. EXA review comm iting list (5 this wil of practices have cussions with SWB t for CT3 staffing 4 actually success	ocess) . (4 reliant on ments- this will II be completed responded) BH and Cobalt (4 (5 will commence sfully recruiting)
<ul> <li>Radiology has the largest number of patients waiting at 7,804 and has the largest number of patient waiting over 6 weeks at 3,222; an increase of 1,557 from Jun-21. This is predominantly due to an increase in patients waiting for a CT scan, up by 991 patients to 2,333 in total.</li> </ul>	MRI staffing low due to sickney backlog	ignificant impact on 2ww and back l ess and leave, resulting in non-contr aff not offering additional sessions i	ast lists only and s	ome reduced sessi	ions with an impa	ct on 2WW and
Activity		ENDOSCOPY (inc. G	0.	ogy)		
<ul> <li>13,873 diagnostic tests were undertaken in Jul-21, 1,610 fewer than Jun-21</li> <li>For radiology, only non-obstetric ultrasound achieved its H1 target, whereas MRI and CT showed further increases in activity but not at the planned level.</li> <li>For endoscopy, none of the three modalities achieved an H1 target, although gastroscopy was able to increase activity from</li> </ul>	<ul> <li>What have we been doing?</li> <li>Continuing the use of IS at BM patients</li> <li>Ceased weekday working and room of activity during weeke week at ECH due to decontam</li> <li>Commenced weekend WLI at weekend WLI at KTC/Alex</li> </ul>	<ul> <li>Resume wee</li> <li>Continue to r</li> <li>Commence r</li> <li>Commence r</li> <li>help reduce o</li> <li>WRH, continued</li> <li>Number of p</li> </ul>	decontamination kday working for 1 recruit to administ ecruitment proces dropped capacity ( atients on waiting	machines at ECH c .8 week w/c 24 Aug rative vacancy. (4) s for an additional 5) list for a procedure ced sedation servi	gust (5) fully trained nurs e under GA – worl	e endoscopist to
<ul><li>the previous month.</li><li>Echocardiography did not met the H1 target.</li></ul>		tpatients are repeatedly being cance g list for a procedure under GA – wo			enhanced sedation	n service.





### **Operational Performance: DM01 Diagnostics**

2.4 - Ensure timely access to diagnostics and treatment for all urgent cancer care



NHS


Worcestershire

**Acute Hospitals** 



### Month 4 [July] 2021-22 | Operational Performance: DM01 Diagnostics

Responsible Director: Chief Operating Officer | Validated for July-21 as 1st September 2021



These graphs represent H1 annual planning restoration only, as submitted in the plan. All other physiology tests, DEXA and cystoscopy were not included in the request from NHSEI.

July-L V2

Enc E 2 IPR-、 21Data\_FINAL

NHS






### **Operational Performance: Diagnostics (DM01) Benchmarking**

**National Benchmarking (June 2021)** | The Trust was one of 4 of 13 West Midlands Trust which saw a decrease in performance between May-21 and May-21 This Trust was ranked 12 out of 13; where we were 13 previous month. The peer group performance ranged from 0.96% to 47.71% with a peer group average of 20.75%; 0.223 from 19.78% the previous month. The England average for May-21 was 22.40% a 0.1% decrease from 22.30% in May-21.

In June, there were 123,962 patients recorded as waiting 13+ weeks for their diagnostic test; 2,235 (1.80%) of these patients were from WHAT



NHS **Operational Performance: Stroke** Worcestershire Acute Hospitals % of patients spending 90% of % of patients who had Direct Admission (via % of patients who had a CT within % patients seen in TIA clinic SSNAP O4  $\sim$ time on a Stroke Ward A&E) to a Stroke Ward 60 minutes of arrival within 24 hours Jan-21 to Mar-21 ш С 72 58 % 37.10% 37.10% 65.57% Score 66.6 Grade ы С ы What does the data tell us? What are we doing to improve? Key Performance Indictors – Monthly Update Patients Admitted Within 4 Hours - This is proving to be challenging due to limited flow to Stroke rehab beds. All four main stroke metrics show performance that is within common The team are working with Health & Care Trust to identify appropriate Rehab patients to improve flow out to the cause variation Health & Care Trust beds. Within the acute Trust, the Neurology patients pathway is being reviewed this month Patients spending 90% of their time on a stroke ward shows no to aim to reduce their length of stay if admitted to Stroke unit. Furthermore, there is variable flow out to the significant change in performance since Apr-18. The process is community stroke team, which decreases the capacity of inpatient stroke beds. A meeting with WMAS will be unlikely to achieve the target of 80% consistently but may be expected to vary between 62% and 92%. The performance of 72.58% arranged in August to share examples of inappropriate pre-alerts. equates to a grade E from SSNAP. 90% Stay on Stroke Ward: Inappropriate pre-alert, late referral from A&E mainly out-of-hours, reduced cover Patients who had Direct Admission (via A&E) to a stroke ward shows out-of-hours makes achieving this challenging. To note, the team provides timely therapy and stroke assessment no significant change in performance since Oct-19. The process will when the patient arrives to the ward. Recruitment is on-going with regards to appointing senior consultants and not achieve the target of 90% but may be expected to vary between currently, in the process of interviewing a consultant and preparing to seek Royal College approval for a joint 14% and 79%. The performance of 37.10% equates to a grade E from consultant post with QE. This should be ready to be advertised end of September. Patients who had a CT scan within 60 minutes of arrival shows no TIA Patients Seen Within 24 Hours: The capacity to run weekend TIA clinic has reduced significantly since last change since Sept-18. The process will not achieve the target of 80% month due to shortage in medical cover, the performance is expected to continue for 2-3 months until further but may be expected to vary between 21% and 72%. The performance consultants are appointed. However, to improve this performance, consultants to triage all TIA referral prior to of 37.10% equates to a grade C from SSNAP. adding patients to the TIA clinic. Currently in the process of updating the referral form to ensure appropriate Patients seen in TIA clinic within 24 hours returned to common cause patients are referred to the service thereby increasing efficiency. variation in Jun-21. It has been demonstrated that this metric can Specialty Review Within 30 Minutes: All stroke related patients presented in ED are reviewed by Stroke CNS & achieve the target consistently with 14 consecutive months above Consultants. The Stroke front door team are dedicated to ensuring all stoke patients presenting in ED are 70% from Mar-20 to Apr-21. This is not a SSNAP metric.

assessed by stroke specialist in-hours and are given a swallow screen within 24 hrs as per national guidance. This

Ż

Data

will be further enhanced when 24/7 CNS cover is introduced, currently going through management of change process. When expected to move to next level of assurance: Moving to assurance level 6 is dependent on achieving the main stroke metrics Current Assurance Level: 5 (Jul-21) and demonstrable improvements in the SSNAP score / grade. Q1 SSNAP will be published in Sept-21. Previous Assurance Level: 5 (Jun-21) SRO: Paul Brennan

SSNAP.


•





### Month 3 [June] | 2021-22 | Operational Performance: Stroke

Responsible Director: Chief Operating Officer | Validated for Jun-21 as 2<sup>nd</sup> August 2021





Please note: These SPC charts have been re-based to evidence if any changes in performance, post the initial COVID-19 high peak, are now common or special cause variation.

- Lockdown Period

29

NHS



Worcestershire Acute Hospitals NHS Trust

 $\sim$ 

c E 2

# **Quality and Safety**

Note: Improvement Slides have not been included as Q&S Committee meetings were cancelled due to Trust operating at Level 4.





### Summary Performance Table | Month 4 [July] 2021-22

Worcestershire Acute Hospitals NHS Trust July-L\_V2

Enc E 2 IPR-21Data\_FINA

Quality and Safety Metrics		Latest Month	Measure	Target	Performance	Assurance	Mean	Lower process limit	Upper process Limit
u	C-Diff	Jul-21	7	4	0g <sup>0</sup> 00	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	4	0	10
Infection Prevention	Ecoli	Jul-21	1	4	<b>~~</b>	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	4	0	10
ection F	MSSA	Jul-21	1	0			2	0	6
1 L	MRSA	Jul-21	0	0		S	0	0	1
	l Acquired Pressure : Serious Incidents	Jul-21	0	-			0	0	2
	Falls per 1,000 bed days causing harm		0.05	0.04		?~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	0	0	0
% medic	% medicine incidents causing harm		3.6	11.71		3.	10	2	18
giene	Hand Hygiene Audit Participation	Jul-21	97.27	100	(a) / 10	S	90	76	103
Hand Hygiene	Hand Hygiene Compliance to practice	Jul-21	99.71	98	H		99	99	100
VTE /	Assessment Rate	Jul-21	97.24	95	(H)	5.5	96	94	98
Sepsis	Sepsis Screening compliance	Jun-21	82.18	95			83	71	95
Sep	Sepsis 6 bundle compliance	Jun-21	61.68	95	000	F	51	25	78
#NOF tim	e to theatre <=36 hrs	Jul-21	64.1	85		?~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	79	60	97
Mortality	Mortality Reviews completed <=30 days		35.5	-			43	20	67
HSMR 12 month rolling average		Mar-21	98.64	-		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	105	102	108
Compla	Complaints responses <=25 days		88.89	80		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	77	44	110
ICE viewed reports		Jun-21	95.61	-	(0, <sup>0</sup> /20)		96	94	98
Ice viewed reports	ICE viewed reports [radiology]	Jun-21	83.55	-			85	81	89

Quality and Safety Metrics	Latest Month	Measure	Target	Performance	Assurance	Mean	Lower process limit	Upper process Limit
FFT A&E Response	Jul-21	14.67	20		~?	17.02	12	22
FFT A&E Recommended	Jul-21	70.9	95	3	F	83.98	77	90
FFT Inpatient Response	Jul-21	33.25	30	(2) (2)	\$	31.78	24	40
FFT Inpatient Recommended	Jul-21	96.04	95	e S	?	95.67	94	98
FFT Maternity Response	Jul-21	19.23	30		?	22.18	5	39
FFT Maternity Recommended	Jul-21	94.78	95		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	95.08	82	108
FFT Outpatients Response	Jul-21	10.8	10	\$3	?	10.43	7	14
FFT Outpatients Recommended	Jul-21	91.85	95	2) 2)	?	93.59	92	95



## Data Quality Risk Matrix – Quality & Safety



July-L V2

Enc E 2 IPR- , 21Data\_FINAL

Data Set	Includes	Likelihood	Impact	Total Score	Context
	C-Diff	1	3	3	
Infection	E-Coli	1	3	3	This data is scrutinised at patient level regularly.
prevention and Control	MSSA	1	3	3	There are no known issues with this data known at present.
	MRSA	1	3	3	
Hand Hygiene	Hand Hygiene Participation Hand Hygiene Compliance	Unknown	Unknown	N/A	Not yet reviewed. Plan to review the completion of these audits from a data quality perspective (Q2 2021/22)
Sepsis	Sepsis 6 bundle Compliance Sepsis Screening Compliance Sepsis Screening Antibiotics	Unknown	Unknown	N/A	Not yet reviewed. Plan to audit the completion of these audits from a data quality perspective. (Q3 2021/22)
VTE	VTE Assessment 24 Hours VTE Assessment	2	2	4	This metric has had a lot of scrutiny and is reviewed fortnightly in a meeting so no concerns.
ICE Deporting	ICE reports viewed radiology	3	2	6	The data quality issue is in relation are in relation to filing and management of reporting by consultants and allocation of report to correct consultant. There are some small technical issues for which there is currently no resolution.
ICE Reporting	ICE reports viewed Pathology	3	2	6	<b>Mitigation:</b> There are reports available on WREN at consultant level to provide focus on which reports require viewing and filing.



## Data Quality Risk Matrix – Quality & Safety



Data Set	Includes	Likelihood	Impact	Total Score	Context
Fractured Neck of Femur	NOF time to theatre	2	3	6	Data is captured robustly in a FNOF national database, the data quality between the clinical PAS and the database can be different, however we routinely audit this.
Falls	Falls per 1,000 bed days causing harm	1	1	2	No data quality issues due to the in depth patient level scrutiny.
Pressure Ulcers	All Acquired Pressure Ulcers Serious Incident Pressure Ulcers	1	1	2	No data quality issues due to the in depth patient level scrutiny.
Medicine Incidents	Total medicine Incidents reports Medicine incidents causing harm	Unknown	Unknown		Not yet reviewed. Plan to audit the completion of these audits from a data quality perspective (Q2 2021/22)
Complaints	Complaints Reponses = 25 days</td <td>Unknown</td> <td>Unknown</td> <td></td> <td></td>	Unknown	Unknown		



## Data Quality Risk Matrix – Quality & Safety



Enc E 2 IPR-21Data\_FINA

Data Set	Includes	Likelihood	Impact	Total Score	Context
	HSMR 12 month rolling	2	2	4	On occasion issues are identified but these are investigated as they arise. No current known issues.
Mortality	Mortally review completed = 30<br days		3	6	<ul> <li>There are still some investigations regarding the accuracy of data in the new bereavement app. Issues may be related to interpretation of how the app should be used and interpretation of which data to record where.</li> <li>Mitigation: Detailed review of the app – mortality working group is systematically working through a review of the app.</li> </ul>
Friends and Family	A&E Responses Rates Inpatient Responses Rates Maternity Responses Rates Outpatients Responses Rates A&E Recommended Rate Inpatient Recommended Rate Maternity Recommended Rate Outpatients Recommended Rate	No score	No score		



	Integrated Quality Performance Report - Headlines
Quality Performance	Comments
Infection Control	<ul> <li><i>C.difficile</i> infections did not achieve the in-month target for Jul-21 (7 vs target 5), and is not achieving the year to date trajectory (25 vs target 18)</li> <li>E-Coli BSI achieved the in-month target for Jul-21 (1 vs target 2), but is not achieving the year to date trajectory (10 vs target 9).</li> <li>MSSA BSI achieved the in-month target for Jul-21 (1 vs target 1), and is achieving the year to date trajectory (5 vs target 5).</li> <li>MRSA BSI achieved the in-month target for Jul-21 (0), and is achieving the year to date trajectory of no infections.</li> <li>The Hand Hygiene audit participation rate rose in Jul-21 to 97.27%, which is the highest achieved in the last 18 months.</li> <li>Hand Hygiene Practice Compliance rate continues to perform above the 98% target, with 99% being exceeded for the last 18 months.</li> <li>Antimicrobial Stewardship performance for Jul-21 achieved the 90% target for the indicators 'Antibiotics within guidelines'(90.69%) and 'Reviewed within 72 Hours' (92.12%)</li> <li>Overall compliance for Antimicrobial Stewardship was 88.63%, which is below the target of 90%.</li> </ul>
SEPSIS 6	<ul> <li>The sepsis 6 bundle completed within one hour compliance rose in Jun-21 (61.68%), but the performance is still below the target (90%).</li> <li>Sepsis 6 screening performance fell very slightly in Jun-21 (82.18%), and has not met the target since May-19.</li> <li>Sepsis 6 antibiotics provided within one hour compliance fell in Jul-21 (89.72%), and it failed to hit the target for the first time in 6 months.</li> </ul>
VTE Assessments	<ul> <li>There has been a sustained improvement in VTE assessments, with the target begin attained every month since April 2019.</li> <li>VTE 24 hour re-assessment rates are still below target, but have been an on upward trend in the last 12 months rising from 54.69% (Aug-20) to 71.28% (Jul-21).</li> </ul>
ICE Reporting	<ul> <li>The Target of 95% for viewing Radiology Reports on ICE has not been achieved in the past 15 months (range 80.56% to 84.21%).</li> <li>The Target of 95% for viewing Pathology Reports on ICE has been achieved for 12 consecutive months (range 95.61% to 97.24%).</li> </ul>
Fractured Neck of Femur	<ul> <li>The #NOF target of 85% has not been achieved since the start of the pandemic in Mar-20 (87.30%), and fell in Jul-21 (64.1%) after improving for the previous 3 months.</li> <li>Performance has been over 80% for 3 of the 13 months since the start of the Pandemic, peaking in Jan-21 (80.72%) with a trough in Jul-21 (64.10%).</li> </ul>

35

Enc E 2 IPR- July-21Data\_FINAL\_V2


	Integrated Quality Performance Report - Headlines	IDR- III/-
Quality Performance	Comments	С Ц
Friends & Family Test	<ul> <li>The recommended rate exceeded the 95% target for Inpatients for the 13th month out of the last 14 (the remaining month was only just under at 94.87%)</li> <li>The recommended rate for Maternity dropped in Jul-21 (94.78%) and just missed the 95% target.</li> <li>The recommended rate for Outpatients dropped to 91.85% in Jul-21. Although still above 90%, this is the 7<sup>th</sup> consecutive month which has seen a small fall (from 95.68% in Jan-21).</li> <li>The recommended rate for A&amp;E dropped for the 3rd month to 70.90%. Prior to this period it has been above 83% for 12 months.</li> </ul>	U U
Complaints	• The % of complaints responded to within 25 days fell slightly in Jul-21 to 88.89%, but was still above target (80%).	
Hospital Acquired Pressure Ulcers (HAPU)	<ul> <li>There were zero Serious Incident HAPU's in Jul-21 for the 5<sup>th</sup> consecutive month.</li> <li>There were zero Category 4 HAPU's in Jul-21 for the 12<sup>th</sup> consecutive month.</li> <li>The monthly target for total HAPUs was achieved with 15 HAPUs in Jul-21.</li> <li>The total of 50 HAPUs year to date is well under the year to date trajectory of 82.</li> </ul>	
Falls	<ul> <li>The number of falls per 1000 bed days increased in Jul-21 to 4.98, but is still below the national benchmark of 6.63.</li> <li>The total number of falls is achieving the year to date trajectory (387 vs target 411).</li> <li>The number of SI falls per 1000 bed days increased in Jul-21 to 0.05, but is still below the national benchmark of 0.19.</li> <li>The total number of SI falls is failing to achieve the year to date trajectory (3 vs target 1).</li> </ul>	





### Month 4 [July] | 2021-22 Quality & Safety - Care that is Safe

Responsible Director: Chief Nursing Officer, Chief Medical Officer | Validated for July-21 as 12<sup>th</sup> August 2021



Variation Special Cause High n Low High Low Special Cause High Low Special Cause High Low Special Cause Special Special Cause Special Sp

Lockdown Period COVID Wave








### Month 4 [July] | 2021-22 Quality & Safety - Care that is Safe

Responsible Director: Chief Nursing Officer, Chief Medical Officer | Validated for July-21 as 12th August 2021



Variation Assurance P -Lockdown Period COVID Wave

38

July-V2

FINAL

Enc E 2 21Data\_

 $\sim$ 

NHS



### Month 4 [July] | 2021-22 Quality & Safety - Care that is Effective

Responsible Director: Chief Nursing Officer, Chief Medical Officer | Validated for July-21 as 12<sup>th</sup> August 2021



Variation Baccal Baccal Control Con

Page 106 of 182

39

July-V2

FINAL

NHS



### Month 4 [July] | 2021-22 Quality & Safety - Care that is Effective

July-L\_V2

FINAL


Enc E 2 2104

NHS

40

Worcestershire Acute Hospitals

Responsible Director: Chief Nursing Officer, Chief Medical Officer | Validated for July-21 as 12<sup>th</sup> August 2021



COVID Wave





WHS Worcestershire Acute Hospitals NHS Trust July-V2

Enc E 2 IPR-21Data\_FINA

# Maternity





# Data Quality Risk Matrix – Maternity



July-V2

Enc E 2 IPR-21Data\_FINA

Data Set	Includes	Likelihood	Impact	Total Score	Context
Pregnancy bookings	<ul> <li>Trust bookings</li> <li>Bookings before made before 12wks + 6days gestation</li> </ul>				Paper pregnancy notes weren't migrated to Badgernet so when those women deliver and are 'booked' onto the system, our booking figures are being inflated.
		4 (no change)	3 (no change)		The recording of women booked to deliver at the Trust, those receiving antenatal care only and transfers of care is under review. Incorrect booking figures have an impact on service delivery and planning.
				12 (no change)	Booking figures have changed (risen) for previously reported months when refreshed.
					<b>Mitigation:</b> Figures have been adjusted by referencing previous maternity system data. The pregnancies of the green notes cohort have concluded and this is now a historic issue. It is recommended that the service updates the date of entry to the backdated/correct booking date. An audit of booking classifications will be undertaken, with the service and information department currently investigating and monitoring whether backdated bookings are being recorded; accounting for the changes in previous months booking figures.
Deliveries	<ul> <li>Total deliveries</li> <li>Home deliveries</li> <li>Vaginal deliveries</li> <li>Instrumental (Ventouse &amp; Forceps) deliveries</li> <li>Total Caesareans</li> <li>Elective Caesareans</li> <li>Emergency Caesareans</li> <li>Induced deliveries</li> </ul>	2 (changed from 3)	2 (changed from 3)	4 (changed from 9)	<ul> <li>The recording of women delivering at the Trust and those receiving postnatal care only having delivered elsewhere is under review.</li> <li>Some caesareans are missing classification (emergency / elective) details.</li> <li>There are discrepancies in the data on inductions due to the multiple ways of recording this in the BadgerNet system.</li> <li>Higher delivery figures on Badgernet will impact the coding process by making it appear that there are deliveries that haven't been created as admissions on OASIS and the Trust delivery activity as being higher than actually occurred.</li> <li>Mitigation: Figures have been adjusted by applying business logic to back-end data. Further refinement of logic is on-going and will be reviewed and signed off by the Service . Advice and guidance on the key fields used to identify Trust and non-Trust activity in BadgerNet has been fed back to the maternity service by the information department.</li> </ul>






# Data Quality Risk Matrix – Maternity

Worcestershire Acute Hospitals uly-V2

2 IP

Enc E 2 21Data

Data Set	Includes	Likelihood	Impact	Total Score	Context
Births	<ul> <li>Total births</li> <li>Stillbirths</li> <li>Pre-term births</li> <li>Admission of term babies to Neonatal care</li> </ul>	3 (no change)	2 (no change)	6 (no change)	The correct recording of babies not born at the Trust, where postnatal care is being provided by the Trust, is under review. This affects the total births denominator used in the reporting of safety related ratios for stillbirths, pre-terms and term admissions to neonatal care <b>Mitigation:</b> Figures have been adjusted by applying business logic to back- end data. Further refinement of logic is ongoing and will be reviewed and signed-off by the Service. Advice and guidance on the key fields used to identify Trust and non-Trust activity in BadgerNet has been fed back to the maternity service by the information department.
Governance & Safety	<ul> <li>Maternal deaths</li> <li>Neonatal Deaths</li> </ul>	2 (changed from 3)	3 (changed from 5)	6 (changed from 15)	Maternal deaths will always be identified via the PAS system/national reporting / coroner as not all deaths that require investigation occur in our hospital. Maternal deaths will then be aded to Badgernet, with the Digital Midwife leading on education on this and the processes are in place to QA with the Governance Team. Following a review of all of the neonatal deaths by the Director of Midwifery and Chief Nursing Officer it was confirmed that the additional cases (where the gestation was <24 <sup>+0</sup> weeks with signs of life) were sadly terminations for fetal anomalies that are not included in national reporting (but are still submitted to MBRRACE). The reporting of neonatal deaths is now correct as there is clarity on the definitions and a monthly cross check with the W&C Governance team is established.






### Month 4 [July] 2021-22 Maternity



Neonatal % admission of full-Deaths Booked before tern babies to Stillbirths Maternal Deaths % Pre-term births % Home births Births (>24<sup>+0</sup> weeks 12+6 weeks neonatal care gestation) 3.3% 1 1 0 6.2% 3.6% 78.1% 418 What does the data tell us? What have we been doing? There has been no statistical change in the percentage of unexpected term admissions to Streamlined booking process in Redditch & Bromsgrove to improve KPI the neonatal unit . Monitoring pipeline of new starters and August start dates confirmed for some . There have been no maternal deaths and one neonatal death recorded in Jul-21. . Develop process to monitor delays in IOL pathway Sadly, there was 1 stillbirth and will be reviewed via PMRT process. . Providing evidence as requested for NHSEI support programme – diagnostic phase was . There has been no statistical change in the percentage of pre-term births completed in mid-July . Home births has moved back within normal process limits for the first time in 7 months; . Reduced sickness absence rates (non COVID) the difference between Jun-21 and Jul-21 is only 2 home births. 3.6% is still higher than . Improvement plan agreed at Board performance observed before the step change in Oct-20. CNST declaration 10/10 submitted . Last month the % of births by elective caesarean was identified as special cause variation; • Received £317K from Ockenden to support further increase in maternity staffing to this has returned to normal variation in Jul-21. support training • Only the % mothers booked before 12<sup>+6</sup> weeks gestation continues to show special cause What are we doing next? variation. A process review has been undertaken as there were differences in approach Launch improvement plan within Directorate and commence workstreams across the community teams. • Advertise new posts funded by Ockenden Prepare planned spending against CNST monies . Develop reporting process to Board to reflect all requirements of the perinatal . surveillance model When expected to move to next level of assurance: Following evidence submission to NHSEI for Ockenden and position confirmed Review of IOL pathway complete Current Assurance Level: 5 (Jul-21) Review of SoP for CoC complete No midwifery vacancies/reduce sickness absence levels Complete improvement plan **Previous Assurance Level:** 5 (Jun-21) SRO: Paula Gardner (CNO)

-ylu








45

July-L V2

FINAL

Enc E 2 2 21Data\_F

 $\sim$ 



Enc E 2 IPR- July-21Data\_FINAL\_V2

Page 113 of 182





Enc E 2 I 21Data\_F


# **Learning From Deaths**





### **Learning from Deaths - Headlines**


Learning From Deaths	Comments
SHMI	<ul> <li>SHMI = 1.0233 (Mar 2020 – Feb 2021) and remains well within 'expected range' at Trust-wide and site level. In respect of our overall SHMI we continue to sit within the middle of our (previously identified) 'mortality peers'.</li> <li>We remain something on an outlier for out-of-hospital deaths (within 30 days of discharge) as both a % of all mortality and associated SHMI. Although this has no apparent negative impact on our SHMI. Extensive analysis and enquiry have thus far ruled out any malevolent explanations (internal or community based).</li> <li>No areas (eg. diagnostic groups) are highlighted for concern. On the contrary, Congestive heart failure (non-hypertensive) and Cancer of Bronchus are highlighted with a lower than expected SHMI (ie. fewer deaths than 'expected'. Short-term projections suggest that our SHMI is unlikely to worsen demonstrably over the coming months.</li> </ul>
HSMR	<ul> <li>HSMR = 98.64 (Apr 2020 – Mar 2021) and is within 'expected range' and below the 'expected' number of inpatient deaths for this period.</li> <li>There was one possible CUSUM/early warning alert in respect of our HSMR. This relates to Abdominal pain but is likely to be a product of delayed or incomplete coding at the time of our HES submission [note: this turned out to be the case]</li> <li>Like SHMI, our HSMR is mid-placed compared to our mortality peers and is unlikely to worsen substantially over the coming months.</li> <li>That both standardised models of mortality are well within their 'expected range' suggests that, global pandemic notwithstanding, we are not seeing any unusual trends in mortality (note: SHMI and HSMR do not include deaths directly relating to Covid-19).</li> </ul>
Crude mortality (inc. Covid-19)	<ul> <li>Crude mortality paints a slightly inconsistent picture with some areas improving whilst others worsen (albeit only slightly).</li> <li>As we move through the pandemic and past the peak of wave 2 we can see that our monthly crude mortality rate (inc. Covid-19) and Covid-19 crude mortality rate have improved.</li> <li>Our crude mortality rate for out-of-hospital Covid-19 deaths increased very slightly. Whilst this does not impact our SHMI, it does corroborate our out-of-hospital mortality being somewhat out of kilter with our overall mortality trends.</li> <li>We also have a slightly elevated crude mortality rate when compared to our SHMI peers and the national average.</li> <li>Early July saw a slight rise in inpatient deaths compared to the five-year average and is/was not attributable to Covid-19. This follows on from three consecutive months (Apr – Jun) with fewer than average deaths. This will be explored in subsequent reports.</li> </ul>
Other mortality	<ul> <li>Our Standardised Paediatric Mortality Index (SPMI = 139.54), whilst within expected range has increased for the second consecutive month (since we have been monitoring this). It is also noticeably higher than our mortality peers. This will be reviewed in more detail in subsequent reports.</li> <li>Pulmonary embolic deaths are unchanged and are similar to that reported nationally and by our SHMI peers.</li> </ul>
Learning from deaths	<ul> <li>Whilst we are witnessing a growing backlog in completed mortality reviews (a consequence of the pandemic), those completed reviews show that the vast majority are graded 3 (adequate) or better.</li> <li>For the period Dec 2020 to Jun 2021 there was just one SJR with an overall care grade of 1 (very poor) and 23 with a grade of 2 (poor). This compares with 280 reviews with an overall care score of 4 (good) and 85 with a score of 5 (excellent). Future reporting will explore the reviews in more detail.</li> </ul>
Ongoing / future work	<ul> <li>A Mortality Information Working Group was established in May with the aim of providing timely, accurate and reliable information in support of the Divisional mortality and morbidity meetings and identifying any key changes to the current (new) bereavement application.</li> <li>A bereavement/mortality dashboard has been created and changes to the bereavement application are scheduled for completion and user testing in early September.</li> <li>Future analysis/reporting will focus on crude mortality, a review of the SPMI and exploring the findings of the SJR process. This moves us from reliance on historic reporting to understand mortality.</li> </ul>





### **Learning From Deaths**






Our SHMI continues to be favourable (ie. well within the expected range stipulated by the model) and we remain toward the middle of our previously established 'mortality peers'.






### **Learning From Deaths**



Our crude inpatient mortality has tracked at or below the five year average since the end of wave 2 (although has risen slightly in early July).

For three consecutive months (Apr-Jun) our crude inpatient mortality has been below that which we would ordinarily expect (ie. compared to 5yr average).



50

NH

2 IP

ш


Enc 21Da

Data



#### **Learning From Deaths**





For those SJRs completed between Dec 2020 and June 2021 the quality of care described remains mostly good or excellent.





Enc E 2 IPR- J 21Data\_ FINAL 21Data\_ FINAL

July-L\_V2

# Workforce





# **Data Quality Risk Matrix - Workforce**



July-L V2

Enc E 2 IPR- 、 21Data\_FINAL

Data Set	Includes	Likelihood	Impact	Total Score	Context
	Appraisal (Non-Medical)	3	1	3	We are confident in the reporting which is from nationally created ESR BI reports. However, there have been issues with accuracy of recording by Managers on Self Service. This is addressed by training/screenshots and a supplementary IT link for sending appraisal through for inputting in L&D. Monthly reports are sent to Managers and both Managers and Staff can validate on ESR Self Service.
	Medical Appraisal	1	1	1	There is manual intervention to remove doctors in training but no current issues identified.
Workforce	Mandatory Training	3	1	3	We are confident in reporting which is from Competencies set up on OLM and pulled through nationally created BI reports from ESR. However, there are periodic issues reported where staff cannot access training due to IT issues which are resolved individually. Mitigation is for L&D to validate Monthly data and provide commentary on any IT/operational issues.
Compliance	Consultant job plans	2	1	2	We are confident in reporting from Allocate e-Job Plan. However, compliance is low due to lack of job planning, or late reporting. Dedicated Job Planning Officer role now in post to review/audit and improve compliance.
	Staff turnover	Staff turnover 3			We are confident in reporting via nationally created BI report. Delays in managers submitting Starter and Leaver forms do result in retrospective adjustment which has been addressed by changing timescale to require forms 8 weeks before start/leave. Annual Payroll audit by CW Audit takes place of Starter and Leaver forms. Monthly Payroll meeting reviews late forms which affect pay.
	Covid risk assessment compliance 4		2	6	There have been issues with the recording of Risk Assessments due to forms not being received, or actioned in a timely manner in Occupational Health due to increased workload. Weekly reports were sent to Divisions for validation. These currently appear to be resolved. There are remaining issues with timeliness of forms for New Starters which is escalated with Divisions.





## Data Quality Risk Matrix - Workforce



July-

Enc E 2 IPR- 21Data\_FINAL

Data Set	Includes	Likelihood	Impact	Total Score	Context
	<ul> <li>Substantive Vacancy Rate</li> <li>Total Vacancies Rate (including Bank and Agency)</li> <li>[Source: Finance ADI]</li> </ul>	2	1	2	Vacancies are recorded in the Oracle Finance Ledger and extracted using the ADI. A Vacancy in terms of IPR is a post that is not filled substantively and needs to be recruited to. A vacancy will be Establishment minus Contracted. ADI is a manual process which extracts data from Oracle. Oracle is updated by an automated ESR feed to Oracle each month for substantive staff (weekly for bank). ADI is reviewed by Senior Finance colleagues every month on Day 5 and the Ledger shuts and is signed off on Day 7. We are confident with the process and the checks and balances in place.
	• Growth in Establishment [Source: Finance ADI]	2	1	2	Establishment is recorded in the Oracle Finance Ledger and extracted using the ADI in terms of budget and wte. The process for agreeing changes to budgets is through Business Cases to TME. ADI is a manual process which extracts data from Oracle. The ADI is reviewed by Senior Finance colleagues every month and we are confident with the process and the checks and balances in place.
	Total hours worked [Source: Finance ADI]	5	2	10	Hours worked for temporary staff feed is a manual process into the Ledger from data extracted from the NHSP portal. There have been issues with the reporting of wte hours worked from NHSP which have been escalated and are being regularly reviewed. The implementation of Allocate Locum on Duty and 247 Time in 2020 highlighted this problem.
Workforce Performance	<ul> <li>Monthly staff sickness absence</li> <li>% Staff absent due to stress and Anxiety</li> <li>[Source: ESR/Allocate HealthRoster]</li> </ul>	3	3	9	Sickness (and all absence) from 1st April 2021 are recorded through HealthRoster by Managers. An Absence interface to ESR pulls through once per month on payroll upload. Weekly meetings to review project progress and testing of data pulled through interface. There have been issues identified historically of late or non-reporting of absence which are investigated individually. The full rollout of Rostering to all staff should help to address this. However, this is reliant on Managers inputting roster changes in a timely manner so will require regular review by e-Rostering team.
	<ul> <li>Number of Covid sickness</li> <li>Number Self Isolating</li> <li>[Source: WREN/Allocate</li> <li>HealthRoster]</li> </ul>	3	3	9	These absences have been recorded on HealthRoster since Wave 1 of Covid Pandemic, initially via a Covid Absence Line, and latterly by Managers with rollout of HealthRoster to all staff groups. There were issues initially of late and non-reporting which are being addressed through full rollout of Rostering. Intermittent issues of incorrect categorisation of absence is picked up individually with managers by e-Rostering Team.
	<ul> <li>Bank Spend as % of Gross Cost</li> <li>Agency Spend as a % of Gross Cost [Source: Finance]</li> </ul>	2	1	2	Bank and Agency Spend as a % of Gross cost is calculated by Finance colleagues from the Ledger which is signed off by Senior Finance colleagues through a formal process each month.
	• Maternity/Adoption Leave [Source: ESR]	3	3	9	We are confident of the report which is from a nationally created ESR BI report. However, there is intermittent late reporting of both the commencement and end of maternity leave which is reviewed through Payroll meeting monthly as they impact on Maternity Pay.






Enc E 2 IPR- July-21Data\_FINAL\_V2

People & Culture	Comments
Getting the basics right (appraisal, mandatory training, job plans)	<ul> <li>Mandatory training compliance continues to exceed current Trust target at 91%</li> <li>Medical appraisal compliance has dropped to 88% but remains above Model Hospital average of 85%.</li> <li>Non-medical appraisal rate has remained at 82%</li> <li>There has been an 1% improvement in Consultant Job Planning to 67% but we are still performing below Model Hospital average</li> </ul>
Drivers of Bank & Agency spend	<ul> <li>We have a 349 wte increase in establishment compared to the same period last year due to funding of new wards, Covid and business cases at budget setting</li> <li>Our vacancy rate of 9.7% is above the ONS national average of 8.1%. The increase has been driven by the increase in establishment in April and May.</li> <li>There are 181 staff on maternity leave compared to 135 staff for the same period last year. This is an increase of 16 in one month. 53 of these are registered nurses and 25 are HCA's which will be driving bank and agency spend on the wards.</li> <li>Monthly Sickness is 5.4% which is 1.06% higher than the same period last year.</li> <li>The current annual turnover rate is 9.41% which is 1.63% better than the same period last year.</li> </ul>
Staff Health & Wellbeing	<ul> <li>Cumulative sickness has increased to 4.77% with Covid</li> <li>Sickness due to S10 (stress and anxiety) increased by 0.12% to 1.37%</li> <li>Our staff health and wellbeing offer continues to be communicated to staff at every opportunity</li> <li>Location by Vocation pilot is progressing with 570 staff on the pilot</li> <li>Sickness rates for Administrative and Clerical Staff on the LBV pilot are 2.09% compared to 5.04% for those not on the pilot</li> <li>Flexible Working opportunities are being recorded on ESR</li> <li>Staff have started to book their Thank You Day through HealthRoster.</li> <li>91% of our staff have had the first Covid vaccine and 84% have had their second vaccine</li> </ul>





July-L\_V2

FINAL

2

Enc E 2 | 21Data\_F





### Workforce Compliance Month 4 (July 2021): - What does the data tell us?



		Acute	
Consultant Job Planning	Annual Staff Turnover	Covid Risk Assessment Compliance	Enc E 2 21Data_
67%	9.41%	91%	

#### What does the data tell us?

Appraisal and

**Medical Appraisal** 

82% and 88%

• Appraisal – Compliance remains unchanged at 82% but is 7% higher than the same period last year.

**Mandatory Training and Core** 


**Essential to Role Training** 

91% and 85%

- Medical Appraisal Medical appraisal has dropped by 3% to 88 % this month but is 16% higher than the same period last year
- Mandatory Training Mandatory Training compliance has remained unchanged at 91% this month which is 5% better than the same period last year
- Essential to Role Training Essential to Role training has improved by 1% to 85%.
- Consultant Job Plans Consultant job planning compliance has improved this month by 1% to 67% and is 13% higher than the same period last year. SCSD and Surgery and Speciality Medicine have improved this month but Women and Children's has dropped by 25%.. Urgent Care is the only division that meets the 90% target.
- Staff Turnover Staff annual turnover has deteriorated by 0.13% this month to 9.41% which is 1.63% better than the same period last year. Monthly turnover at 0.81% is better than Model Hospital average of 0.98% where we are in the 2<sup>nd</sup> quartile
- Covid Risk Assessment Compliance Compliance has declined by 1% to 91% this month

National Benchmarking (July 2021) Model Hospital Benchmark for Mandatory Training compliance is 90% and a peer group average of 88% so the Trust is better than average. Performance is better than Model Hospital average of 85% for Medical Appraisal. We remain an outlier for job planning and non-medical appraisal.









58

July-L V2

IPR-,

Enc E 2 21Data\_1





Arrow depicts direction of travel since last month. Green is improved, Red is deteriorated and amber unchanged since last month.





### Workforce Performance Month 4 - What does the data tell us?



What does the data tell us?

- Vacancy Rate Vacancy rates have reduced by 0.45% this month to 9.7%. Our funded establishment has reduced this month by 33 wte but is 349 wte higher than the same period last year when we had a total vacancy rate of 4.44%. We employ broadly the same wte staff in post as last year but the increase in establishment at budget setting is the reason for increased vacancy rate.
- Total Hours Worked The total hours worked for substantive, bank and agency staff increased by 8 wte to 6283 wte. Bank has increased by 37 wte and agency has reduced by 4.88 wte with extra hours by substantive reducing by 23 wte.
- Monthly Sickness Absence Rate Sickness has increased by 0.81% to 5.4% which is 1.06% worse than the same period last year. Cumulative sickness has increased to 4.77% from 4.65%.
- Absence due to Stress and Anxiety (S10) Absence due to stress and anxiety has increased by 0.12% to 1.37% this month which is 0.22% better than the same period last year in the early months of Wave 1 of the pandemic
- Absence due to Covid Sickness (S27) 15 staff were absent due to Covid symptoms at the end of July compared to 11 at the end of May. This figure includes those staff who have reported sick due to effects of the Covid vaccine. Absence due to self isolation (including family symptoms and Test and Trace) was 77 compared to 24 at the end of June. The trend is reducing from a peak in mid July of 116.
- Maternity/Adoption Leave We continue to see a steady increase in the number of staff on maternity or adoption leave since the start of the pandemic with 181 currently off compared to 165 last month. compared to 134 for the same period last year. 53 of these are Registered Nurses and 25 HCA's which will be impacting on ward bank and agency spend.
- Bank and Agency Spend as a % of Gross Cost this month has seen a positive growth in bank spend to 7.38% of gross cost. Agency Spend has reduced by 0.42% to 7.79% this month but this is still 0.29% higher than the same period last year. Urgent care has improved by 5.1% but remains an outlier with 19.37% of its gross staffing costs being agency spend.

#### National Benchmarking (July 2021)

We remained good at Quartile 2 on Model Hospital for overall sickness with 3.91% compared to 3.92% national average (March 2021 data). Monthly turnover improved on Model Hospital from 4<sup>th</sup> Quartile to 2<sup>nd</sup> Quartile (0.84% compared to national average of 0.98% (May 2021 data)

NHS

Worcestershire Acute Hospitals





### Annual Plan Strategic Objectives: Workforce

Worcestershire Acute Hospitals Enc E 2 IPR- July-21Data\_FINAL\_V2

Strategic Wo	rkforce Plan	BAME Workforce	Organisational Development
Introduce new roles and staffing models to support the delivery of our clinical services strategy	Accelerate new ways of working from the Covid-19 experience	Undertake Covid-19 Risk Assessments for all BAME staff	Implement new operational management structure
	al and are suitably trained with up to dat	e job plans. Ensure we have adequate staf tive staff and reduce reliance on bank and	
How have we been doing?		What improvements will we make	?
	directly due to increased establishment of bank and agency usage which is a resu ss absence s an increase of 16 staff	<ul> <li>leave management and categor</li> <li>E-Rostering Team are managing requires manual intervention for</li> <li>We will continue to work with d are encouraged to take up the Q</li> <li>We will continue with the imple reduce premium staffing costs</li> <li>We will continue with the Locat</li> <li>We will continue to improve red HealthRoster and ESR</li> <li>L&amp;D and Workforce colleagues review the eligibility for Safeguar</li> </ul>	the payment process for Thank You day which or enhancements. livisions to ensure 95% of patient facing staff Covid vaccine ementation of the Best People Programme to ion by Vocation Pilot cording of flexible working opportunities on have met with the relevant topic leads to arding Level 2 Training and Moving and Handlin s will be reflected on the competency matrix
Overarching Workforce Performance L Previous Assurance Level - 5 – June 20	-	To work towards improvement to	next assurance level





# Finance





## **Our Financial Position** | Headlines

Finance	Comments
2021/22 Financial Plan	Given the positive YTD M2 variance across the system, CFOs agreed to offset beneficial YTD M2 variances against the unmitigated system risk in H1 (£6.4m); for us this was £1.8m. A further assessment of ERF achievement was performed following a re-submission of activity. This resulted in a further benefit to our position of £1m. <b>Our H1 revised plan, inclusive of ERF is a £1.1m surplus.</b> Our YTD position combined with our operational forecast for M5 and M6 indicates a H1 deficit of £(1.9)m - <b>£3m adverse to plan</b> . Our profiled plan assumed that COVID related expenditure would decrease. This planning variance coupled with increased costs in response to COVID is the key drivers of this adverse variance.
Elective Recovery Fund	Q1 has been restated based on latest coded data resulting in the posting of a further £1.3m of ERF income in month. We are now estimating £2.7m YTD in line with the H1 plan. Q2 estimates remain at zero following the change in guidance from 85% to 95% - except for any movement to the June value once all activity is coded.
Productivity and Efficiency	We have so far not received any formal updated planning guidance for H2. However, an increased waste reduction requirement is likely to be applied. In the absence of published guidance national briefing suggests a planning assumption of efficiency in the order of 3% for H2. Schemes to achieve this level have not been identified. H2 planning will include Specialty self-assessment packs to identify opportunities.
H2 Budget	Both the ICS and the Trust continue to work on the H2 budget. The Trust awaits clarification regarding funding. It is unlikely that the H2 budget will be available for approval before October 2021.
Temporary staffing	There has been an increase in Nursing Bank as a result of COVID bed provision and absenteeism. Daily staffing escalation calls continue with last resort escalation to off framework agencies.
Cash	Good cash balances continue, rolling forecasting well established, achieving BPPC target, positive SPC trends on aged debtors and cash. Risks remain around sustainability given evolving regime for H2 2021/22 and beyond.
Capital	Significant capital schemes continue and require ongoing robust programme management to ensure delivery. Commitment monitoring remains in place and prioritisation of schemes is nearing completion.



## Finance | Key Messages

COVID-19 Due to the continuing COVID-19 pandemic, a revised COVID-19 financial framework will be in place for H1 21/22. System funding envelope, comprising adjusted CCG allocations, system topup and COVID-19 fixed allocation, based on the H2 2020/21 envelopes adjusted for known pressures and policy priorities. Block payment arrangements will remain in place and signed contracts between NHS commissioners and NHS providers are not required for the H1 2021/22 period. NHS England and NHS Improvement have nationally calculated CCG and NHS provider organisational plans for the H1 period as a default position for systems and organisations to adopt.

H1 2021/22 Internal Plan

Delivery of the H1

**Internal Financial** 

Plan

The 2021/22 operational financial plan for H1 has been developed from a roll forward of the recurrent cost and non patient income budget from 2019/20 adjusting for an assessment of PEP delivery in 2020/21 and the recurrent impact, identification of cost pressures and an assessment of legacy and approved business cases in 2020/21. We have then overlaid the impacts of additional Covid expenditure (and additional Covid income) and PEP schemes developed by the Divisions. The final step has been to adjust for vacancy factors, activity levels lower than 2019/20 and any slippage in Business cases. **Our initial submission to the system for H1 showed a deficit position of £(2.9)m** this was reassessed to £1.1m surplus including ERF in M2. **Following the bottom up forecasting process undertaken by the Divisions in July we have reassessed this position to a £(1.9)m deficit at M4.** 

#### Month 4 – July Position

	Jul	21 (Month	4)	Y			
Statement of Comprehensive Income	H1 Plan	Actual	Var to Plan	H1 Plan	Actual	Var to Plan	H1 Plan
	£000s	£000s	£000s	£000s	£000s	£000s	£000s
Operating Revenue & Income							
Operating income from patient care activities	44,798	45,624	826	178,583	179,117	534	267,84
Other operating income	1,879	2,195	316	7,740	8,634	894	11,58
Operating Expenses							
Employee expenses	(26,880)	(27,353)	(473)	(108,139)	(108,869)	(730)	(162,007
Operating expenses excluding employee expenses	(17,979)	(18,176)	(197)	(71,019)	(71,432)	(413)	(106,844
OPERATING SURPLUS / (DEFICIT)	1,818	2,290	472	7,165	7,449	284	10,57
Finance Costs							
Finance income	1	0	(1)	4	0	(4)	
Finance expense	(1,025)	(1,025)	(0)	(4,100)	(4,098)	2	(6,148
Movement in provisions	0	0	0	0	0	0	
PDC dividends payable/refundable	(571)	(670)	(99)	(2,284)	(2,383)	(99)	(3,426
Net Finance Costs	(1,595)	(1,695)	(100)	(6,380)	(6,481)	(101)	(9,568
Other gains/(losses) including disposal of assets	0	0	0	1	12	11	
SURPLUS/(DEFICIT) FOR THE PERIOD/YEAR	223	595	372	786	980	194	1,00
Less impact of Donated Asset Accounting (depreciation only)	10	14	4	30	55	25	4
Adjusted financial performance surplus/(deficit) inc PSF, FRF, MRET & Top-Up	233	609	376	816	1,036	220	1,05

Following the bottom up forecasting process undertaken by the Divisions in July we have reassessed this position to a £1.9m deficit at M4.

#### I&E Delivery Assurance Level: Level 4

Against the H1 operational plan of £1.1m, YTD at month 4 (July 2021) we report an **actual surplus of £1m** against the plan £0.8m surplus. **Favourable variance of <u>£0.2m</u>**.

- Combined Income £1.4m above YTD plan of which £1.0m favourable due to ERF and £0.5m Covid O/S envelope reimbursement for Pathology Testing.
- Employee expenses £0.7m adverse to YTD plan despite £0.5m favourable from business case slippage. Pay costs remain in line with M2 and M3 with £0.1m additional in WLI being offset by £0.1m lower substantive pay costs and £0.1m additional Bank spend offset by £0.1m lower Agency.
- Operating expenses £0.4m adverse to YTD plan. £1.3m adverse on Non PbR Drugs being offset by favourable variances caused by Business Case slippage (£0.5m) and Covid (£0.3m).

Increased operating variances in M4 driven by a reduced Operating expense plan. Overall expenditure levels are consistent with last month despite a planning assumption that Covid costs would decrease and PEP delivery would increase.

**Reason:** H1 plan deficit of c.£(2.9)m reassessed to £1.1m surplus. Forecast £(1.9)m deficit. Risks remains over costs of delivering additional activity and the level of temporary staffing expenditure to deliver the activity and respond to the current wave of Covid admissions in the Trust. Controls remain. POSITIVE Financial variance in month. PEP & Temp Staffing remain challenged. Underlying deficit consistent.






## Finance | Key Messages



65


The Combined Income (including PbR pass-through drugs & devices and Other Operating Income) was £1.1m above the Trust's Internal operational plan in July.



**£8.9m additional System COVID/top up payment** was received from Commissioners to cover additional costs of COVID and to fulfil the STP breakeven requirement (will continue until September 2021). Trust also can qualify for further funding should the STP achieve activity thresholds set by NHSE & I under the Elective Recovery Fund framework (ERF). The Trust's estimate of the YTD achieved is **£2.7m** (reported in the position). Although system performance will not confirmed until it has been validated by NHSE & I.

To date April's achievement has been confirmed however the same the methodology (shared by NHSE & I) has been applied to derive the financial value for the remaining months.

**In month variance £1.1m** - £0.7m EFR (£0.4m April's confirmed higher than expected and £0.3m coding catch-up), £0.3m NHSE Drugs & Devices (a retrospective adjustment for final settlement of 2020/21) and £0.1m COVID PCR testing income.



- Month 12 adjusted to remove the following one off items: 6.3% pension adjustment (£12.1m); Provisions for unused annual leave (£3.9m); Consultant job plan updates (£0.7m); Overtime holiday pay entitlements following the settlement of the Flowers legal claim (£0.5m); Central PPE stock adjustment (£6.4m); Impairment losses (£6.6m); and Contract exit costs (£0.2m).
- Above chart excludes Non PbR items.





## **Finance** | Key Messages

luly-V2

Enc E 2 IPR- 、 21Data\_FINAL

Capital expenditure for month 4 of financial year 2021/22 is £6.143m, with the majority relating to spend on projects carried over from the previous financial year. The 2021/22 Capital Plan is £51.69m for the financial year, including IFRIC 12. Funding of £6.113m is currently at risk until we have received confirmation from NHSEI that our application has been successful. The remainder of the plan includes the in-year works on the new Urgent and Emergency Care scheme, plus the ASR project subject to Ful Business Case national approval. The prioritisation of schemes to ensure we address regulatory risks, infrastructure backlog and replacement of end of life equipment will continue via our CPG in the context of the available resources and the risk of further expenditure requirements coming forward as we progress through the year.										l that our ect to Full ment will					
											g remains in plac	ce and			
105     Overall BPPC Performance       100     -       95     -						At the end of July 2021 the cash balance was £36.8m (including un cleared payments of (£2.9m), with £2.1m of capital PDC drawn down this month.					of				
90 85 80 Feb-20 Apr-20 Jun-20 Aug-20 Oct-20 Dec-20 Feb-21 Apr-21 Jun-21					Cash Assurance Level:       Level 6         Reason:       Good cash balances, rolling CF forecasting well established, achieving BPPC target, positive SPC trends on aged debtors and cash. Risks remain around sustainability given evolving regime for H2 2021/22 and beyond.										
Our internal opera	tional plan f	or H1 is inc	lusive of	£5.4m of	annual Pro	ductivity	and Effi	ciency pla	ns. Plans f	for the H1	L period (	M1 – M6)	total £2m	I.	
	Apr-21 M1	May-21 M2	Jun-21 M3	Jul-21 M4	Aug-21 M5	Sep-21 M6	Oct-21 M7	Nov-21 M8	Dec-21 M9	Jan-22 M10	Feb-22 M11	Mar-22 M12	FY TOTAL	]	
	Monthly A	djusted Expenditure Produc		COVID 2 <sup>50</sup> Wave	2 tech Case Concern	Adjus COVI follov going July h activi	sted Exp D signific w produc g forward has seen ity has re	enditure F cantly imp ctivity cha I. the WAU cmained a	Productivit acts our s nges thro remain co t the simi	t <u>y Trend:</u> pend aga ugh COVI postant. E lar levels	inst weig D recover xpenditur of admiss	hted activ ry and to t re is the s ions and	rity. This lo track again ame level ED attenda	ocal metric allo ist forecasted a as June and the	ctivity • WAU
	2021/22 Capital Pli application has bee Business Case nation continue via our Cl Capital Assurance Reason: Significant prioritisation of sch 100 95 90 85 80 Feb-20 Apr-20 Ju	2021/22 Capital Plan is £51.69 application has been successfu Business Case national approvi continue via our CPG in the co Capital Assurance Level: Reason: Significant capital sche prioritisation of schemes nearin Overall E 90 90 95 90 85 80 Feb-20 Apr-20 Jun-20 Aug-20 Our internal operational plan f M1 PEP Profile £000's 155	2021/22 Capital Plan is £51.69m for the fi application has been successful. The remander Business Case national approval. The prior continue via our CPG in the context of the Capital Assurance Level: Level 5 Reason: Significant capital schemes continu- prioritisation of schemes nearing completion 00 Porrall BPPC Perfor 00 Performander 00 Performander 0	2021/22 Capital Plan is £51.69m for the financial y application has been successful. The remainder of Business Case national approval. The prioritisation continue via our CPG in the context of the available Capital Assurance Level: Level 5 Reason: Significant capital schemes continue into 20 prioritisation of schemes nearing completion. Risk re 105 100 95 90 85 80 Feb-20 Apr-20 Jun-20 Aug-20 Oct-20 Dec-20 Feb- Our internal operational plan for H1 is inclusive of Apr-21 May-21 Jun-21 M1 M2 M3 PEP Profile £000's 158 169 328	2021/22 Capital Plan is £51.69m for the financial year, inclu application has been successful. The remainder of the plan Business Case national approval. The prioritisation of schem continue via our CPG in the context of the available resource Capital Assurance Level: Level 5 Reason: Significant capital schemes continue into 2021/22 and prioritisation of schemes nearing completion. Risk remains in 105 00 verall BPPC Performance 100 95 90 85 80 Feb-20 Apr-20 Jun-20 Aug-20 Oct-20 Dec-20 Feb-21 Apr-21 Our internal operational plan for H1 is inclusive of £5.4m of 100 100 101 102 103 103 104 104 104 104 105 106 106 107 108 109 108 109 109 109 109 100 100 100 100 100 100	2021/22 Capital Plan is £51.69m for the financial year, including IFRIC 1 application has been successful. The remainder of the plan includes the Business Case national approval. The prioritisation of schemes to ensur continue via our CPG in the context of the available resources and the r Capital Assurance Level: Level 5 Reason: Significant capital schemes continue into 2021/22 and will require prioritisation of schemes nearing completion. Risk remains in medium terr overall BPPC Performance 0 5 5 6 6 7 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7	2021/22 Capital Plan is £51.69m for the financial year, including IFRIC 12. Funding application has been successful. The remainder of the plan includes the in-year Business Case national approval. The prioritisation of schemes to ensure we add continue via our CPG in the context of the available resources and the risk of funding of the context of the available resources and the risk of funding of the context of the available resources and the risk of funding of the context of the available resources and the risk of funding of the context of the available resources and the risk of funding of the context of the available resources and the risk of funding of the context capital Assurance Level: Level 5 Reason: Significant capital schemes continue into 2021/22 and will require robust prioritisation of schemes nearing completion. Risk remains in medium term.  At the f2.9m  For the formation of the formation of the fact of	2021/22 Capital Plan is £51.69m for the financial year, including IFRIC 12. Funding of £6. application has been successful. The remainder of the plan includes the in-year works on Business Case national approval. The prioritisation of schemes to ensure we address reg continue via our CPG in the context of the available resources and the risk of further exp <b>Capital Assurance Level:</b> Level 5 Reason: Significant capital schemes continue into 2021/22 and will require robust programm prioritisation of schemes nearing completion. Risk remains in medium term.	2021/22 Capital Plan is £51.69m for the financial year, including IFRIC 12. Funding of £6.113m is complication has been successful. The remainder of the plan includes the in-year works on the new Business Case national approval. The prioritisation of schemes to ensure we address regulatory ris continue via our CPG in the context of the available resources and the risk of further expenditure expenditure via our CPG in the context of the available resources and the risk of further expenditure expenditure significant capital schemes continue into 2021/22 and will require robust programme manager prioritisation of schemes nearing completion. Risk remains in medium term.  At the end of July 2021 (£2.9m), with £2.1m of The high cash balance is Cash Assurance Level Schemes for the scheme for H is inclusive of £5.4m of annual Productivity and Efficiency pla to be the financial yar. The scheme for H is inclusive of £5.4m of annual Productivity and Efficiency pla to be the financial yar. The scheme for the	2021/22 Capital Plan is £51.69m for the financial year, including IFRIC 12. Funding of £6.113m is currently a application has been successful. The remainder of the plan includes the in-year works on the new Urgent an Business Case national approval. The prioritisation of schemes to ensure we address regulatory risks, infras continue via our CPG in the context of the available resources and the risk of further expenditure requirement Capital Assurance Level: Level 5 Reason: Significant capital schemes continue into 2021/22 and will require robust programme management to en- prioritisation of schemes nearing completion. Risk remains in medium term. At the end of July 2021 the cash (£2.9m), with £2.1m of capital PI The high cash balance is the resul Cash Assurance Level: Level Beb-20 Apr-20 Jun-20 Aug-20 Oct-20 Dec-20 Feb-21 Apr-21 Jun-21 Our internal operational plan for H1 is inclusive of £5.4m of annual Productivity and Efficiency plans. Plans to Mathematical Mathematical Math	2021/22 Capital Plan is £51.69m for the financial year, including IFRIC 12. Funding of £6.113m is currently at risk unti application has been successful. The remainder of the plan includes the in-year works on the new Urgent and Emerg Business Case national approval. The prioritisation of schemes to ensure we address regulatory risks, infrastructure I continue via our CPG in the context of the available resources and the risk of further expenditure requirements com Capital Assurance Level: Level 5 Reason: Significant capital schemes continue into 2021/22 and will require robust programme management to ensure del prioritisation of schemes nearing completion. Risk remains in medium term. At the end of July 2021 the cash balance v (£2.9m), with £2.1m of capital PDC drawm The high cash balance is the result of the t Cash Assurance Level: Level 6 Reason: Good cash balances, rolling CF fi positive SPC trends on aged debtors and evolving regime for H2 2021/22 and beyr Our internal operational plan for H1 is inclusive of £5.4m of annual Productivity and Efficiency plans. Plans for the H2 V Ma	2021/22 Capital Plan is £51.69m for the financial year, including IFRIC 12. Funding of £6.113m is currently at risk until we have application has been successful. The remainder of the plan includes the in-year works on the new Urgent and Emergency Care Business Case national approval. The prioritisation of schemes to ensure we address regulatory risk, infrastructure backlog and continue via our CPG in the context of the available resources and the risk of further expenditure requirements coming forward Capital Assurance Level: Level 5 Reason: Significant capital schemes continue into 2021/22 and will require robust programme management to ensure delivery. Corprioritisation of schemes nearing completion. Risk remains in medium term. The high cash balance is the result of the timing of response to the time of the timing of response to the time of the timing of re	2021/22 Capital Plan is £51.69m for the financial year, including IFRIC 12. Funding of £6.113m is currently at risk until we have received application has been successful. The remainder of the plan includes the in-year works on the new Urgent and Emergency Care scheme, Business Case national approval. The prioritisation of schemes to ensure we address regulatory risks, infrastructure backlog and replace continue via our CPG in the context of the available resources and the risk of further expenditure requirements coming forward as we prioritisation of schemes continue into 2021/22 and will require robust programme management to ensure delivery. Commitment prioritisation of schemes nearing completion. Risk remains in medium term.           105       Overall BPPC Performance         106       Overall BPPC Performance         107       Dec 20         108       Dec 20         109       Overall BPPC Performance         109       Dec 20         109       Dec 20         100       De	2021/22 Capital Plan is £51.69m for the financial year, including IFRIC 12. Funding of £6.113m is currently at risk until we have received confirmat application has been successful. The remainder of the plan includes the in-year works on the new Urgent and Emergency Care scheme, plus the A Business Case national approval. The prioritisation of schemes to ensure we address regulatory risks, infrastructure backlog and replacement of e continue via our CPG in the context of the available resources and the risk of further expenditure requirements coming forward as we progress the Capital Assurance Level: Level 5 Reason: Significant capital schemes continue into 2021/22 and will require robust programme management to ensure delivery. Commitment monitoring prioritisation of schemes nearing completion. Risk remains in medium term.	2021/22 Capital Plan is £51.69m for the financial year, including IFRIC 12. Funding of £6.113m is currently at risk until we have received confirmation from NHSE application has been successful. The remainder of the plan includes the in-year works on the new Urgent and Emergency Care scheme, plus the ASR project subjustices Scae national approval. The prioritisation of schemes to ensure we address regulatory risks, infrastructure backlog and replacement of end of life equip continue via our CPG in the context of the available resources and the risk of further expenditure requirements coming forward as we progress through the year on the new Urgent and Emergency Care scheme, plus the ASR project subjustices Scaes national approval. The prioritisation of schemes to ensure we address regulatory risks, infrastructure backlog and replacement of end of life equip continue via our CPG in the context of the available resources and the risk of further expenditure requirements coming forward as we progress through the year of schemes to continue into 2021/22 and will require robust programme management to ensure delivery. Commitment monitoring remains in plan prioritisation of schemes to continue into 2021/22 and will require robust programme management to ensure delivery. Commitment monitoring remains in plan prioritisation of schemes to continue into 2021/22 and will require robust programme management to ensure delivery. Commitment monitoring remains in plan prioritisation of schemes to cost programme management to ensure delivery. Commitment monitoring remains in plan prioritisation of schemes to cost programme management to ensure delivery. Commitment monitoring remains in plan prioritisation of schemes to cost programme management to ensure delivery. Commitment monitoring remains in plan prioritisation of schemes to cost programme management to ensure delivery. Commitment monitoring remains in plan prioritisation of schemes to cost prioritisation of schemes to cost prescent prioritisation of schemes to cost priorit







July-V2

Ż


Enc E 2 I 21Data\_F

# **Appendices**





### **Statistical Process Charts (SPC) Guidance**



Orange dots signify a statistical cause for concern. A data point will highlight orange if it:

A) Breaches the lower warning limit (special cause variation) when low reflects underperformance or breaches the upper control limit when high reflects underperformance.

B) Runs for 7 consecutive points below the average when low reflects underperformance or runs for 7 consecutive points above the average when high reflects underperformance.

C) Runs in a descending or ascending pattern for 7 consecutive points depending on what direction reflects a deteriorating trend.

#### Blue dots signify a statistical improvement. A data point will highlight blue if it:

A) Breaches the upper warning limit (special cause variation) when high reflects good performance or breaches the lower warning limit when low reflects good performance.

B) Runs for 7 consecutive points above the average when high reflects good performance or runs for 7 consecutive points below the average when low reflects good performance.

C) Runs in an ascending or descending pattern for 7 consecutive points depending on what direction reflects an improving trend.

**Special cause variation** is unlikely to have happened by chance and is usually the result of a process change. If a process change has happened, after a period, warning limits can be recalculated and a step change will be observed. A process change can be identified by a consistent and consecutive pattern of orange or blue dots.



68

Worcestershire Acute Hospitals



## Levels of Assurance



July-1 V2

Enc E 2 IPR- 21Data\_FINAL

<b>RAG</b> Rating	ACTIONS	OUTCOMES
	Comprehensive actions identified and agreed upon to	Evidence of delivery of the majority or all the agreed actions,
Level 7	address specific performance concerns AND recognition of	with clear evidence of the achievement of desired outcomes
	systemic causes/ reasons for performance variation.	over defined period of time i.e. 3 months.
	Comprehensive actions identified and agreed upon to	Evidence of delivery of the majority or all of the agreed
Level 6	address specific performance concerns AND recognition of	actions, with clear evidence of the achievement of the
	systemic causes/ reasons for performance variation.	desired outcomes.
	Comprehensive actions identified and agreed upon to	Evidence of delivery of the majority or all of the agreed
Level 5	address specific performance concerns AND recognition of	actions, with little or no evidence of the achievement of the
	systemic causes/ reasons for performance variation.	desired outcomes.
	Comprehensive actions identified and agreed upon to	Evidence of a number of agreed actions being delivered, with
Level 4	address specific performance concerns AND recognition of	little or no evidence of the achievement of the desired
	systemic causes/ reasons for performance variation.	outcomes.
	Comprehensive actions identified and agreed upon to	Some measurable impact evident from actions initially taken
Level 3	address specific performance concerns AND recognition of	AND an emerging clarity of outcomes sought to determine
	systemic causes/ reasons for performance variation.	sustainability, agreed measures to evidence improvement.
Level 2	Comprehensive actions identified and agreed upon to	Some measurable impact evident from actions initially taken
Level 2	address specific performance concerns.	Some measurable impact evident from actions initially taken.
Level 1	Initial actions agreed upon, these focused upon directly	Outcomes sought being defined. No improvements yet
Lever I	addressing specific performance concerns.	evident.
Level 0	Emerging actions not yet agreed with all relevant parties.	No improvements evident.









**8,230** Walk-in patients (A&E)



12,331

Telephone consultations



**Emergency Operations** 



4,770

Patients arriving by ambulance

418

Babies



JULY 2021 IN NUMBERS

> **12,243** Inpatients

**1,470** Elective operations

**27,999** Face to Face outpatients



**200** Trauma Operations





NHS

NHS Trust

Worcestershire Acute Hospitals

Page 137 of 182

5.6

Average length of stay



**Pressure Ulcers** 

CDIFF

7

All hospital acquired 15 0





before midday

17.40

A&E Inpatients

Maternity Outpatients 10.80




**Complaints Responses** </=25 days

88.89

**Recommended Rate** 70.90 tients 96.04 ernity Outpatients








HSMR 12 months 98.64 rolling (March21)

Mortality Reviews 35.50 completed </=30 days (Nov-20)





ECOLI

1

Falls per 1,000 bed days

causing harm

1

Risks overdue review 118 **Risks with** 178 overdue actions

**Putting Patients First** 

MRSA

0

**ICE** reports viewed

95.61

83.55

Radiology

Pathology

**Response Rate** 

14.67	A&E
33.25	Inpa
19.23	Mate







Page 138 of 182

NHS

NHS Trust

Worcestershire

**Acute Hospitals** 

# **Putting Patients First**

## **WORKFORCE COMPOSITION IN NUMBERS**

July 2021





Employees

6,655



**Registered nurses** 1,883 (28%)



Over age 55

18%



**BAME employees** 

17.%

**Registered midwives** 

266 (4%)




HCAs, helpers and assistants

1,291 (19%)



30 years and under







Part-time workers

45%

Doctors

699 (11%)



Female С 82%



Other clinical and scientific staff 842 (13%)



Staff with 20 years service or over

10%

Page 139 of 182